Vizex Investments Ltd
financial consultations

Last news

Transenterix announces 1st US sale

Nov 13, 2017 14
November 13th. Transenterix Inc…

We no longer recommend Array Biopharma Inc

Nov 11, 2017 10
November 11th 2017. We are withdrawing…

Short term investment recommendation -- Alphabet Inc (NASDAQ:GOOGL)

May 22nd  Alphabet Inc. is a holding company. The Company's businesses include Google Inc. (Google) and its Internet products, such as Access, Calico, CapitalG, GV, Nest, Verily, Waymo and X. The Company's segments include Google and Other Bets. The Google segment includes its Internet products, such as Search, Ads, Commerce, Maps, YouTube, Google Cloud, Android, Chrome and Google Play, as well as its hardware initiatives. The Google segment is engaged in advertising, sales of digital content, applications and cloud offerings, and sales of hardware products. The Other Bets segment is engaged in the sales of Internet and television services through Google Fiber, sales of Nest products and services, and licensing and research and development (R&D) services through Verily. It offers Google Assistant, which allows users to type or talk with Google; Google Maps, which helps users navigate to a store, and Google Photos, which helps users store and organize all of their photos.

 

On the date of our recommendation May 22nd the stock could be bought at $958

 

On May 26th the shares could be sold at $993.58

 

Investors profit 3.6%

 

The recommendation is no longer valid

Short term investment recommendation -- Statoil ASA (NYSE:STO)

May 14th  Statoil ASA (Statoil) is an energy company. The Company is engaged in oil and gas exploration and production activities. The Company's segments include Development and Production Norway (DPN), Development and Production International (DPI), Marketing, Midstream and Processing (MMP) and Other. DPN segment manages the Company's upstream activities on the Norwegian continental shelf (NCS) and explores for and extracts crude oil, natural gas and natural gas liquids. DPI segment manages the Company's upstream activities that are not included in the DPN and Development and Production USA (DPUSA) business areas. MMP segment manages its marketing and trading activities related to oil products and natural gas, transportation, processing and manufacturing, and the development of oil and gas. Other segment includes activities in New Energy Solutions (NES), Technology, Projects and Drilling (TPD), Global Strategy and Business Development (GSB), and Corporate staffs and support functions.

 

On May 15th the shares could be bought at $18

 

On May 19th the shares could be sold at $18.23

 

Investors profit 1.2%

 

The recommendation is no longer valid

Short term investment recommendation -- TTM Technologies, Inc

May 7.  TTM Technologies, Inc. is a manufacturer of printed circuit board (PCB) products and is focused on technologically advanced PCBs and electro-mechanical solutions (E-M Solutions). As of January 2, 2017, the Company operated a total of 25 specialized facilities in North America and China. 

 

May 8 shares could be bought at $16.4

May 11 shares could be sold at $16.55

 

Investors profit 0.9%

 

The recommendation is no longer valid

Short term investment recommendation -- Baxter International Inc

April 29th 2017 Baxter International Inc (NYSE.BAX)  through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products. The Renal business offers a portfolio to meet the needs of patients with end-stage renal disease, or irreversible kidney disease and acute kidney injuries, including technologies and therapies for peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapy (CRRT) and additional dialysis services. Its products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices and by patients at home under physician supervision

 

On May 1st - the day we published the recommendation - the stock could be bought at 55.43$ per share.

On May 5th - the stock could be sold at 56$ per share

Investors profit 1% 

The recommendation is no longer valid. 

Вайзекс Инвестментс ООД © 2015 | Всички права запазени